Intellia and CRISPR Therapeutics weigh in on adverse patent ruling regarding CRISPR/Cas9 – Seeking Alpha
|
Intellia and CRISPR Therapeutics weigh in on adverse patent ruling regarding CRISPR/Cas9
Seeking Alpha Intellia Therapeutics (NASDAQ:NTLA) and CRISPR Therapeutics (NASDAQ:CRSP), along with Caribou Biosciences and ERS Genomics, say that the Patent Trial and Appeal Board (PTAB) terminated the interference proceeding related to gene editing … |
